US 12,447,152 B2
Pharmaceutical combination of PRMT5 inhibitors
Mandar Ramesh Bhonde, Pune (IN); Venkata P. Palle, Pune (IN); and Rajender Kumar Kamboj, Pune (IN)
Assigned to Lupin Limited, Mumbai (IN)
Appl. No. 17/767,270
Filed by Lupin Limited, Mumbai (IN)
PCT Filed Oct. 22, 2020, PCT No. PCT/IB2020/059921
§ 371(c)(1), (2) Date Apr. 7, 2022,
PCT Pub. No. WO2021/079302, PCT Pub. Date Apr. 29, 2021.
Claims priority of application No. 201921042899 (IN), filed on Oct. 22, 2019.
Prior Publication US 2022/0395508 A1, Dec. 15, 2022
Int. Cl. A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/454 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/454 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61P 35/00 (2018.01)] 3 Claims
 
1. A synergistic pharmaceutical combination selected from:
(a) compound (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (Compound-24) or a pharmaceutically acceptable salt thereof, and Afatinib,
(b) compound (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (Compound-24) or a pharmaceutically acceptable salt thereof, and BI-3406, and
(c) compound (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (Compound-24) or a pharmaceutically acceptable salt thereof, and Ulixertinib.